HighTower Advisors
GALT icon

HighTower Advisors’s Galectin Therapeutics GALT Stock Holding History

HighTower Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,000
Closed -$2K – 2264
2018
Q3 		$2K Buy
+1,000
New +$5.5K ﹤0.01% 2246

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

HighTower Advisors's GALT Position: Q1 2026 in Review

HighTower Advisors increased its Galectin Therapeutics (GALT) stake by 5.7% in Q1 2026, buying an estimated $15.2K and bringing the position to 93,375 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #3291.

HighTower Advisors first reported a position in GALT in Q3 2018 and has held it in 7 quarters since. The position peaked at $374K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • HighTower Advisors held 93,375 shares of Galectin Therapeutics worth $261K as of Q1 2026.
  • HighTower Advisors bought 5,000 Galectin Therapeutics shares in Q1 2026, an estimated $15.2K.
  • Galectin Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3291 holding.
  • HighTower Advisors first reported a position in Galectin Therapeutics in Q3 2018 and has held it in 7 quarters since.
  • HighTower Advisors's Galectin Therapeutics position peaked at $374K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.